Traumakine for prevention of mortality among operated rupture of abdominal aorta aneurysm (RAAA) patients

Trial Profile

Traumakine for prevention of mortality among operated rupture of abdominal aorta aneurysm (RAAA) patients

Planning
Phase of Trial: Phase I/II

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Aneurysm
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Apr 2017 New trial record
    • 29 Mar 2017 According to a Faron Pharmaceuticals media relase, the company has initiated filing of clinical trial application for the use of Traumakine in a second indication for the prevention of mortality among operated RAAA (Rupture of Abdominal Aorta Aneurysm) patients.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top